Last reviewed · How we verify

Bupivacaine HCl Treatment 1c — Competitive Intelligence Brief

Bupivacaine HCl Treatment 1c (Bupivacaine HCl Treatment 1c) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management.

phase 2 Local anesthetic Voltage-gated sodium channels Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine HCl Treatment 1c (Bupivacaine HCl Treatment 1c) — Durect. Bupivacaine HCl is a local anesthetic that works by blocking sodium channels in nerve fibers to prevent the initiation and transmission of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bupivacaine HCl Treatment 1c TARGET Bupivacaine HCl Treatment 1c Durect phase 2 Local anesthetic Voltage-gated sodium channels
dexmedetomidine-esketamine-ropivacaine combination 1 dexmedetomidine-esketamine-ropivacaine combination 1 Peking University First Hospital marketed Combination anesthetic/analgesic Alpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels
Trileptal® Trileptal® Teva Pharmaceuticals USA marketed Anticonvulsant; sodium channel blocker Voltage-gated sodium channels
Benzocaine oral gel 20% Benzocaine oral gel 20% Dina Youssef Attia marketed Local anesthetic Voltage-gated sodium channels
Surgeon-Initiated Local Anesthetic Surgeon-Initiated Local Anesthetic University of Wisconsin, Madison marketed Local anesthetic Voltage-gated sodium channels
Intracervical lidocaine Intracervical lidocaine Bayero University Kano, Nigeria marketed Local anesthetic Voltage-gated sodium channels
MgSO4 plus Ropivacaine MgSO4 plus Ropivacaine Hospital Universiti Sains Malaysia marketed Local anesthetic adjuvant combination Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine HCl Treatment 1c — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-hcl-treatment-1c. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: